Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1984 1
1986 1
1994 1
2002 1
2008 1
2010 2
2012 1
2016 1
2017 1
2018 1
2019 4
2020 5
2021 9
2022 6
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Cerebrovascular damage in subjective cognitive decline: A systematic review and meta-analysis.
Pitti H, Diaz-Galvan P, Barroso J, Badji A, Olofsson JK, Westman E, Ferreira D, Cedres N. Pitti H, et al. Among authors: cedres n. Ageing Res Rev. 2022 Dec;82:101757. doi: 10.1016/j.arr.2022.101757. Epub 2022 Oct 12. Ageing Res Rev. 2022. PMID: 36240992 Free article. Review.
BACKGROUND: Subjective cognitive decline (SCD) has been postulated as an early marker of Alzheimer's Disease (AD) but it can also be associated to other non-AD pathologies such as Vascular Dementia (VaD). ...
BACKGROUND: Subjective cognitive decline (SCD) has been postulated as an early marker of Alzheimer's Disease (AD) but it can also be …
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.
Ponce S, Cedrés S, Ricordel C, Isambert N, Viteri S, Herrera-Juarez M, Martinez-Marti A, Navarro A, Lederlin M, Serres X, Zugazagoitia J, Vetrhus S, Jaderberg M, Hansen TB, Levitsky V, Paz-Ares L. Ponce S, et al. Among authors: cedres s. J Immunother Cancer. 2023 Sep;11(9):e007552. doi: 10.1136/jitc-2023-007552. J Immunother Cancer. 2023. PMID: 37661097 Free PMC article. Clinical Trial.
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
Nadal E, Bosch-Barrera J, Cedrés S, Coves J, García-Campelo R, Guirado M, López-Castro R, Ortega AL, Vicente D, de Castro-Carpeño J. Nadal E, et al. Among authors: cedres s. Clin Transl Oncol. 2021 May;23(5):980-987. doi: 10.1007/s12094-020-02532-2. Epub 2021 Feb 4. Clin Transl Oncol. 2021. PMID: 33538989 Free PMC article. Review.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Kindler HL, Novello S, Bearz A, Ceresoli GL, Aerts JGJV, Spicer J, Taylor P, Nackaerts K, Greystoke A, Jennens R, Calabrò L, Burgers JA, Santoro A, Cedrés S, Serwatowski P, Ponce S, Van Meerbeeck JP, Nowak AK, Blumenschein G Jr, Siegel JM, Kasten L, Köchert K, Walter AO, Childs BH, Elbi C, Hassan R, Fennell DA. Kindler HL, et al. Among authors: cedres s. Lancet Oncol. 2022 Apr;23(4):540-552. doi: 10.1016/S1470-2045(22)00061-4. Lancet Oncol. 2022. PMID: 35358455 Free PMC article. Clinical Trial.
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.
Yamamoto N, Hayashi H, Planchard D, Morán T, Gregorc V, Dowell J, Sakai H, Yoh K, Nishio M, Cortot AB, Benhadji KA, Soni N, Huang J, Makris L, Cedres S. Yamamoto N, et al. Among authors: cedres s. Invest New Drugs. 2020 Oct;38(5):1588-1597. doi: 10.1007/s10637-020-00930-5. Epub 2020 Apr 3. Invest New Drugs. 2020. PMID: 32246224 Free PMC article. Clinical Trial.
DCR was similar between groups (TAS-114/S-1 80.3%, S-1 75.9%) and median OS was 7.92 and 9.82 months for the TAS-114/S-1 and S-1 groups, respectively (HR 1.31, 95% CI 0.80-2.14; P = 0.1431). The ORR was higher in the TAS-114/S-1 group than the …
DCR was similar between groups (TAS-114/S-1 80.3%, S-1 75.9%) and median OS was 7.92 and 9.82 months for the TAS-114/S- …
Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients.
Cedres S, Serna G, Gonzalez-Medina A, Valdivia A, Assaf-Pastrana JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Priano I, Fasani R, Guardia X, Gonzalo J, Carbonell C, Frigola J, Amat R, Navarro V, Dienstmann R, Vivancos A, Nuciforo P, Felip E. Cedres S, et al. Cancers (Basel). 2023 Jul 14;15(14):3611. doi: 10.3390/cancers15143611. Cancers (Basel). 2023. PMID: 37509274 Free PMC article.
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC, Popat S, Janssens A, Gervais R, Hochstenbag M, Silva M, Burger IA, Prosch H, Stahel R, Xenophontos E, Pretzenbaher Y, Neven A, Peters S. Girard N, et al. Among authors: cedres s. ESMO Open. 2023 Jun;8(3):101576. doi: 10.1016/j.esmoop.2023.101576. Epub 2023 Jun 6. ESMO Open. 2023. PMID: 37285717 Free PMC article. Clinical Trial.
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.
Carbonell C, Frigola J, Pardo N, Callejo A, Iranzo P, Valdivia A, Priano I, Cedrés S, Martinez-Marti A, Navarro A, Lenza L, Soleda M, Gonzalo-Ruiz J, Vivancos A, Sansó M, Carcereny E, Morán T, Amat R, Felip E. Carbonell C, et al. Among authors: cedres s. Mol Oncol. 2023 May;17(5):779-791. doi: 10.1002/1878-0261.13409. Epub 2023 Mar 21. Mol Oncol. 2023. PMID: 36852704 Free PMC article.
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer.
Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-Illescas D, Pardo N, Navarro A, Martinez-Marti A, Cedres S, Carbonell C, Frigola J, Amat R, Felip E. Iranzo P, et al. Among authors: cedres s. Front Med (Lausanne). 2022 May 30;9:875974. doi: 10.3389/fmed.2022.875974. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35707528 Free PMC article. Review.
In recent years, immunotherapy-based regimens have been included into the treatment's algorithm of several cancer types. Programmed death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) interact with their ligands found on the surface of antigen presenting cells (AP …
In recent years, immunotherapy-based regimens have been included into the treatment's algorithm of several cancer types. Programmed d …
46 results